Stereotaxis (STXS) Total Non-Current Liabilities (2010 - 2026)
Stereotaxis (STXS) reported Total Non-Current Liabilities of $29.3 million for Q1 2026, down 21.73% year-over-year from $37.5 million in Q1 2025, and down 9.59% quarter-over-quarter from $32.4 million in Q4 2025.
Stereotaxis (STXS) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Stereotaxis (STXS) has 17 years of Total Non-Current Liabilities data on file, last reported at $29.3 million in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $29.3 million, down 21.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $29.3 million (down 21.73% YoY), and the FY2025 annual result was $32.4 million, down 7.93% from the prior year.
- Total Non-Current Liabilities slipped to $29.3 million in Q1 2026 per STXS's latest filing, from $32.4 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $37.5 million in Q1 2025 and troughed at $19.2 million in Q2 2024.
- A 5-year average of $25.6 million and a median of $21.4 million in 2022 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2025 and 2026: Total Non-Current Liabilities jumped 93.34% in 2025, then declined 21.73% in 2026.
- A 5-year view of Total Non-Current Liabilities shows it stood at $21.4 million in 2022, then fell by 6.94% to $19.9 million in 2023, then surged by 76.62% to $35.2 million in 2024, then dropped by 7.93% to $32.4 million in 2025, then dropped by 9.59% to $29.3 million in 2026.
- Business Quant data shows STXS's Total Non-Current Liabilities at $29.3 million in Q1 2026, $32.4 million in Q4 2025, and $33.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | 1.91 Bn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | 24.24 Bn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | 17.13 Bn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 941.16 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | 1.03 Bn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | 8.65 Bn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | 3.98 Bn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | 2.10 Bn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | 12.54 Bn |
| 10 | Stereotaxis | 180.48 Mn | 165.86 Mn | 3.79 Mn | 29.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.32 Mn |
| Dec 31, 2025 | 32.43 Mn |
| Sep 30, 2025 | 32.95 Mn |
| Jun 30, 2025 | 28.04 Mn |
| Mar 31, 2025 | 37.47 Mn |
| Dec 31, 2024 | 35.23 Mn |
| Sep 30, 2024 | 34.66 Mn |
| Jun 30, 2024 | 19.20 Mn |
| Mar 31, 2024 | 19.38 Mn |
| Dec 31, 2023 | 19.95 Mn |
| Sep 30, 2023 | 20.19 Mn |
| Jun 30, 2023 | 21.30 Mn |
| Mar 31, 2023 | 21.37 Mn |
| Dec 31, 2022 | 21.43 Mn |
| Sep 30, 2022 | 22.56 Mn |
| Jun 30, 2022 | 20.95 Mn |
| Mar 31, 2022 | 19.32 Mn |
| Dec 31, 2021 | 21.34 Mn |
| Sep 30, 2021 | 21.55 Mn |
| Jun 30, 2021 | 15.08 Mn |